Swedish Growth Companies With High Insider Ownership

In This Article:

As European inflation nears the central bank’s target, the Swedish market has shown resilience and potential for growth. In this environment, companies with high insider ownership can be particularly appealing to investors, as they often signal confidence in the company's future prospects. When evaluating stocks in such a market, it's crucial to consider not only their growth potential but also the level of insider ownership. This combination can provide a unique insight into the company’s stability and long-term value creation.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name

Insider Ownership

Earnings Growth

CTT Systems (OM:CTT)

16.9%

24.8%

Truecaller (OM:TRUE B)

29.5%

21.6%

Fortnox (OM:FNOX)

21.1%

22.6%

Magle Chemoswed Holding (OM:MAGLE)

14.9%

72.2%

Biovica International (OM:BIOVIC B)

18.8%

73.1%

BioArctic (OM:BIOA B)

34%

98.4%

Yubico (OM:YUBICO)

37.5%

42.5%

KebNi (OM:KEBNI B)

37.8%

86.1%

InCoax Networks (OM:INCOAX)

19%

115.5%

Calliditas Therapeutics (OM:CALTX)

12.7%

51.9%

Click here to see the full list of 92 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

BioArctic

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) develops biological drugs for central nervous system disorders in Sweden and has a market cap of SEK14.59 billion.

Operations: BioArctic AB generates revenue primarily from its biotechnology segment, amounting to SEK299.35 million.

Insider Ownership: 34%

Earnings Growth Forecast: 98.4% p.a.

BioArctic, a growth company with high insider ownership, has shown significant recent developments. The company's Q2 2024 earnings reported a dramatic increase in sales to SEK 49.84 million from SEK 2.71 million year-over-year, though it still posted a net loss of SEK 68.43 million. Recent phase-1 studies for exidavnemab showed promising results in treating Parkinson's disease, and its Alzheimer's drug Leqembi received multiple international approvals. Revenue is forecasted to grow at an impressive annual rate of 42.4%.

OM:BIOA B Earnings and Revenue Growth as at Sep 2024
OM:BIOA B Earnings and Revenue Growth as at Sep 2024

Humble Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Humble Group AB (publ) refines, develops, and distributes fast-moving consumer products in Sweden and internationally with a market cap of approximately SEK5.60 billion.

Operations: The company's revenue segments include Future Snacking (SEK950 million), Sustainable Care (SEK2.30 billion), Quality Nutrition (SEK1.53 billion), and Nordic Distribution (SEK2.67 billion).